Actively Recruiting
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight
Led by AstraZeneca · Updated on 2026-04-20
871
Participants Needed
3
Research Sites
63 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to assess the safety and tolerability, PK characterisation, efficacy, and immunogenicity of the study intervention, and it allows assessment of the monotherapy or combination therapy of AZD6234 and AZD9550 in different sub-studies.
CONDITIONS
Official Title
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 55 years.
- Body mass index (BMI) 27 kg/m2 or higher.
- Stable body weight for at least 3 months before screening.
- Male and female participants; contraceptive use must follow local regulations.
- Participants must not donate blood during the study and follow-up period.
- Negative pregnancy test at screening and randomisation for females of childbearing potential; must not be breastfeeding.
You will not qualify if you...
- Use of prescription or non-prescription weight loss medication within 3 months before screening.
- History of type 1 or type 2 diabetes or symptoms indicating poor glucose control.
- Treatment with diabetes medication in the past 3 months.
- HbA1c of 6.5% or higher at screening.
- Gastroparesis or similar gastrointestinal conditions requiring treatment.
- Significant inflammatory bowel disease or severe disease/surgery affecting the upper gastrointestinal tract.
- Significant liver disease except certain non-alcoholic liver conditions without complications.
- Abnormal liver function tests exceeding specified limits.
- Previous gallbladder removal or untreated gallstones.
- History of pancreatitis or elevated pancreatic enzymes.
- Severely uncontrolled high blood pressure (systolic ≥160 mmHg or diastolic ≥100 mmHg).
- Resting heart rate below 50 bpm or above 100 bpm.
- Impaired kidney function (eGFR ≤45 mL/min/1.73 m2).
- History of psychosis or bipolar disorder.
- Severe vitamin D deficiency (25-OH vitamin D <12 ng/mL).
- Uncontrolled thyroid disease as judged by the investigator.
- For sub-study 2 only: personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
- Marijuana or THC use within 3 months before screening or unwillingness to abstain during the study.
- Previous psychiatric hospitalization.
- PHQ-9 score of 15 or higher within 2 years before screening or at screening.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Research Site
Jinan, China, 250001
Active, Not Recruiting
2
Research Site
Nanjing, China, 210011
Actively Recruiting
3
Research Site
Shanghai, China, 200032
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here